Clinical Trial Update: Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating inotuzumab ozogamicin with or without donor lymphocyte infusion for relapsed B-lymphoblastic leukemia or lymphoblastic lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• Donor Lymphocyte Infusion
• Inotuzumab ozogamicin (inotuzumab ozogamicin)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Leukemia, Lymphocytic, Acute | Phase 2 | Status: NOT_YET_RECRUITING